Suggested remit: To appraise the clinical and cost effectiveness of trastuzumab deruxtecan within its marketing authorisation for treating HER2-low metastatic or unresectable breast cancer after chemotherapy.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
STA Standard
|
| ID number |
3935
|
Provisional Schedule
| Expected publication |
15 May 2024 |
Project Team
| Project lead |
Thomas Feist |
Email enquiries
| External Assessment Group |
School of Health and Related Research (ScHARR), University of Sheffield |
Stakeholders
| Companies sponsors |
Daiichi Sankyo |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Breast Cancer Now |
| |
METUP UK |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| |
UK Breast Cancer Group (UKBCG) |
| Comparator companies |
Eisai |
| |
Gilead Sciences |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary (BNF) |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
05 March 2024 - 19 March 2024
|
Final draft guidance |
|
05 March 2024
|
Commercial discussions have concluded and the appraisal has resumed. Final Draft Guidance has been issued. |
|
06 December 2023
|
This topic has been paused following the second committee meeting to allow the company and NHSE to engage in commercial discussions. This pause is analogous to that described in section 5.8.34 to 5.8.41 of NICE health technology evaluations: the manual, except that there is no opportunity for further consultation. |
|
07 November 2023
|
Committee meeting: 2 |
|
26 September 2023 - 17 October 2023
|
Draft guidance |
|
05 September 2023
|
Committee meeting: 1 |
|
06 January 2023
|
Invitation to participate |
|
20 October 2022 - 17 November 2022
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
20 October 2022
|
In progress. Scoping commenced. |
For further information on our processes and methods, please see our CHTE processes and methods manual